How Epigenetic Factors Influence Cell Behavior
Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Transforming Cancer Care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford, along with its partner institution, the Cancer Prevention Institute of California. Its nearly 400 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Cancer therapy may work in unexpected way
An antibody to the cell receptor PD-1 may launch a two-pronged assault on cancer by initiating attacks by both T cells and macrophages, a Stanford study has found.
Study finds first possible drug treatment for lymphedema
Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it.
Fibrosis reversed when ‘don’t eat me’ signal blocked
A common signaling pathway unites diverse fibrotic diseases in humans, Stanford researchers have found. An antibody called anti-CD47, which is being tested as an anti-cancer agent, reverses fibrosis in mice.